Clinical Trials
Moderna starts Phase I study of new Covid-19 vaccine candidate
Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study,...
Clinical Trials
TrialScope Welcomes Alexion to Its Growing Clinical Trial Disclosure Community
TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers.
Alexion joins the ranks of...
Clinical Trials
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for...
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of...
Clinical Trials
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. announced initiation of study VLA15-221. The VLA15-221...
Clinical Trials
LSK Global PS Adopts Veeva Vault Clinical Applications to Streamline Global Trial Processes
Veeva Systems announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS,...
Clinical Trials
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Regeneron Pharmaceuticals, Inc. announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma. The...
Articles
The Impact of COVID-19 on Rare Disease Clinical Trials
Barriers and triumphs of an underserved patient group.
It is undeniable that clinical trials for rare diseases are more challenging to design and execute. Unlike trials...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.